🇺🇸 FDA
Pipeline program

BI 764524, Sham Injection Procedure

1436-0007

Phase 2 small_molecule active

Quick answer

BI 764524, Sham Injection Procedure for Diabetic retinopathy is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Diabetic retinopathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials